MagicMed Industries

Overview

In recent years, the psychedelic market has been heating up, increasing investor interest and capital flow into this growing sector. In terms of the market size of psychedelic medicine, it is estimated that it could be as high as US$100 billion. Developing cultural movements, extensive research and policy changes are pushing this rapidly emerging market forward, which is gaining tremendous global and real investor traction.

One unique company in this growing space is MagicMed Industries, a biotechnology company focused on the discovery and early development of novel drug candidates, structurally related to the classic psychedelics but with vastly improved pharmaceutical characteristics and commercial potential. The company intends to establish its flagship molecule derivatives library, the Psybrary™, as an essential building block from which industry partners can develop new patented products.

Psybrary™ is a particularly exciting project considering the resurgence of interest and investment in psychedelics as an alternative mental health therapy in recent years. In 2017, the US Food and Drug Administration (FDA) recognized the potential benefits of MDMA by assigning a Breakthrough Therapy Designation to an MDA-assisted therapy to treat post-traumatic stress disorder (PTSD). Notable government investment and shifting regulatory policy will allow MagicMed to leverage significant institutional support and a growing patient base to explore psychedelic use in a medical capacity.

With a vast library of individual molecules covered by several different chemical compound categories, MagicMed is pursuing partnerships with innovators in the industry to develop newly patented products. These products will help tailor drug candidates to patients’ needs and unlock the healing power of psychedelics. MagicMed has finished its initial derivative portfolio based on the structures of psilocybin and N,N-dimethyltryptamine (DMT). Research efforts continue to create additional patents and derivative portfolios based on MDMA, mescaline, LSD and ibogaine.

To create the novel derivatives contained in the Psybrary™ , the MagicMed team combines synthetic biology and traditional chemistry techniques. This combination allows MagicMed to create a library of molecules that is larger and more diverse than what chemistry techniques alone can achieve. MagicMed analyzes, catalogues, and stores the molecules to find desired characteristics, such as an improved safety profile. Screening a vast library of drug candidates generates a sizeable amount of data that can be processed and used to improve future generations of the Psybrary™.

The company’s diversified approach to molecule manufacturing and market outreach works to de-risk its business model. Making multiple molecules for multiple indications broadens MagicMed’s exposure to numerous specific drug treatments and sectors of the overarching psychedelic market. It’s strategic partnership with the University of Calgary has also benefited the company by providing access to state-of-the-art equipment that the team has been able to utilize.

Next steps for MagicMed include the exciting announcement of a pending public listing on the Canadian Security Exchange in the first or second quarter of 2021. Likewise, the company has been working on new derivatives, patents and first partner engagements since 2020.

MagicMed Industries’ Company Highlights

• MagicMed Industries is a biotechnology company focused on its flagship Psybrary™ project, a library of novel derivative molecules based on classic psychedelics like psilocybin, DMT, mescaline, ibogaine, MDMA and LSD.
• The company’s main objective is advancing the discovery and early development of novel drug candidates structurally similar to classic psychedelics.
• MagicMed has finished it’s initial derivative portfolio based on the structures of psilocybin and N,N-dimethyltryptamine (DMT).
• MagicMed’s diverse approach to molecule manufacturing, revenue generation and market exposure has reduced the company’s business model risk while positioning it for significant economic growth.